The relative importance of these three factors varies in the three sites under discussion, and tumours of the lung, mediastinum and pleura are therefore described separately before the general question of treatment is considered.
The cases available for study are :? .12 (C) Pleural tumours ..... 4 There were in addition ninety-two cases of Hodgkin's lymphadenoma, of which six showed the primary tumour in the mediastinum, and thirty showed secondary involvement of the mediastinum ; also forty-eight cases of lympho-sarcoma, two primary in mediastinum and twelve with generalised involvement of lymph nodes, including the mediastinum.
* Part of thesis submitted for the Fellowship of the British Association of Radiologists.
Two cases of myelogenous leukaemia showed secondary deposits in the lung, and every possible variety of secondary cancer?sarcoma, epithelioma and glandular carcinoma with the rarer conditions, such as seminoma, glioblastoma of the retina and malignant melanoma, all provided examples. Secondary deposits may produce symptoms before the primary growth, and this occurred in two cases of cancer of the stomach and two cases of hypernephroma ; on the other hand, metastases may appear after many years. A giant-cell tumour, locally recurrent, produced, twenty years after excision, a huge mass in the lung ; an osteogenic sarcoma gave multiple deposits thirteen years after amputation, and a metastatic, rapidly fatal chorion-epithelioma showed multiple deposits six years after hysterectomy from a primary so early that the diagnosis was in doubt.
The material has been arranged in relation to two main problems : (i) the pathological nature of the tumour and (2) radiation therapy, and the procedure is to review the literature giving the facts or showing the different views where controversy exists, and then to add new facts which have emerged and which seem to bear on the questions discussed.
The relationship of pathology to treatment is most important, and in many of these cases external radiation is the only possible method of treatment. An attempt has therefore been made to show what types of tumours are likely to be sensitive enough to respond to doses of radiation which can be safely delivered to the lung. I. Pathology.
A. Malignant Tumours of the Lung. Until quite recently two forms of carcinoma of the lung, bronchial and alveolar or parenchymal, have been accepted, and a considerable number of cases of primary sarcoma of the lung have also been recorded. Ewing 1 describes squamous carcinoma and adenocarcinoma, and admits the possibility of a carcinoma primary in the alveoli. He doubts, however, whether a primary sarcoma of the lung exists. Fischer,2 in the text-book of pathology edited by Henke and Lubarsch, says that the possibility of cancer primary in the alveoli cannot be excluded because he accepts an epithelial origin for the lining cells of these air spaces. On the other hand, Fried 3 says that the flattened cells through which the interchange of 96 ?xygen between the blood in the vessels and the air in the alveoli takes place are mesothelial in origin. This view is accepted by Geschickter and Denison4 and by Frissell and Knox,5 who thus discard the term alveolar carcinoma. A point frequently made by those who believe in the bronchial origin of these tumours is that the genetic process from the flattened cells lining the alveoli has never been demonstrated. The production of a layer, or even several layers, of cuboidal cells within the alveolus is not neoplastic, but the normal response of these lining cells to any irritative stimulus. When neoplastic cells are present in the alveoli they are always clearly separated from the walls, as may be seen in Fig. 15 , which illustrates a case diagnosed as " primary alveolar carcinoma." This is one of several cases diagnosed as primary alveolar carcinoma. The material which has been searched for such tumours is considerable, because tissue is available from many cases besides those recorded in the Follow-up Department of the Royal Infirmary, Edinburgh, and in none of these sections was an appearance seen which could be accepted as proof of an alveolar origin. I therefore support the theory that all primary cancer of the lung is bronchogenic. If, however, the cells lining the alveoli are mesothelial they may become sarcomatous, and although nearly all the sarcomas described in older publications were probably undifferentiated carcinomas, Johns and Sharpe 6 have recently described a tumour which they regarded as a sarcoma primary in the mesothelial tissue of the alveoli.
Leaving aside these rare possibilities, cancer of the lung originates in a bronchus or bronchiole. It may be classified by its origin as central, hilar or peripheral, or by its mode of extension as massive or diffuse. Much the commonest of these is the central type, seen when the primary focus is in a first or second division bronchus. Peripheral or diffuse cancers infiltrate the lung parenchyma and may invade the pleura. Such invasion does not exclude a central origin but may conceivably be an expression of origin from a respiratory bronchiole. Figs. I and 2 show invasion of the pleura in a biopsy specimen removed at thoracoplasty for a neoplasm believed to be primary in the pleura. The growth is bronchogenic and shows epidermoid characters, and at autopsy a few weeks later the primary was found in a first division bronchus. N.S. IV., XLVI At first sight it seems strange that such varying cell types may all be derived from the bronchial epithelium, but here we have the pseudo-stratified ciliated epithelium which lines most of the air passages. As described by Maximow,7 this consists of a layer of columnar cells of irregular shape, all of which rest on a basement membrane, but only some of which reach the free surface and develop the typical cilia. This construction makes the nuclei lie at different levels so that the tissue appears to be stratified. The method of cell replacement and of repair in such tissues is not yet certain. There may be areas of undifferentiated proliferating epithelium from which growth takes place, but it seems probable that the small irregular cells which lie near the basement membrane and which are occasionally seen in mitosis, are the stem cells of this tissue. The cells which divide are not in any case the fully differentiated ciliated cells, nor have I seen these fully differentiated cells in any malignant neoplasm. Growth originates in the small stem cells, and it is probable that in this situation with an abundant blood supply all multiplication tends to be very rapid. The cells produced are crowded together, and the shapes and arrangements of round, spindle and oat cell vary according to the conditions prevailing in the area.
Sometimes all three are present in the same tumour.
Another source of polymorphism and probably of giant-cell forms is the abnormal mitosis always seen where growth is rapid. This may be the mode of origin of the undifferentiated cancers, but " differentiation " to squamous cells and keratin formation is not uncommon. This is not true locality differentiation but ectopic?a metaplasia?and it is possible that such a growth arises in a bronchus where metaplasia is already present as a result of chronic irritation. In the 98 f maxillary antrum, metaplasia to squamous epithelium is seen as a result of sepsis. The antrum is lined by pseudo-stratified ciliated epithelium, so it is reasonable to believe that slight chronic bronchitis may also produce a similar change in the bronchi. The nature of metaplasia has been discussed by Fried,3 Borst 8 and others, who believe that the basal cells of the tissue retain the power of producing squamous cells, and Samson 9 talks of " entdifferentiation in bronchogenic carcinoma."
The importance of this is that squamous or epidermoid cancer in this situation is not exactly the same tumour as squamous cancer of the skin. This is illustrated in Fig. 16 , in which metaplasia of the bronchial epithelium is seen in an area where true neoplastic growth is not obvious, while an adjoining area shows the tumour infiltrating the tissue spaces below the columnar epithelium.
The bronchial mucosa is not only a covering tissue ; it also contains numerous mucus-secreting glands, mostly of simple tubular type, and similar to those found in any other mucous membrane. These may give rise to any form of glandular carcinoma, adenocarcinoma with mucus secretion, basal cell or alveolar types, and undifferentiated or medullary carcinoma. In the larger bronchi, malignant polypi are seen with infiltration at the base, and there is a papillary tumour which grows comparatively slowly, but replaces large areas of lung parenchyma. There is a very malignant form which grows very rapidly and may give the picture of bilateral miliary cancer. This rare type is illustrated both by Geschickter and Denison 4 and by Frissell and Knox.5 In both their cases adenocarcinoma with marked production of mucus was found, and it seems that the peculiar method of growth results in the condition of " gelatinous pneumonia " occasionally described in older case records.
Any undifferentiated glandular carcinoma in the lung is likely to metastasise at an early stage, and the metastases are multiple. The order of frequency given by Moise 10 is regional lymph nodes, liver, kidney, lung, pericardium, abdominal lymph nodes, pleura, brain, adrenals, bone, cervical lymph nodes and heart.
The relative frequency of the histological types appears to vary in the different series recorded, but careful analysis shows that it is really the grouping which is different. Henke and Lubarsch (if we except a few unusual tumours) give 99 h 27 per cent, squamous cell cancer, 18 per cent, adenocarcinoma and 55 per cent, undifferentiated cancer, including oat cell, spindle cell, round cell and polymorphic types. Rogers11 reports 40 per cent, squamous cancers, 24 per cent, adenocarcinoma and 36 per cent, undifferentiated, but he includes oat cell tumours as squamous cell types. From the Mayo Clinic 12 the figures are 56 per cent, squamous cell and 44 per cent, adenocarcinoma, but they divide the undifferentiated group. They place the oat-cell and spindle-cell forms in the same group as the squamous cancers and describe a medullary cancer derived from glandular tissues. The term adenocarcinoma is very loosely used, and in most cases may be taken to cover all those glandular carcinomas of almost any type which originate in the mucus glands and mucous surfaces. Of our own cases in which biopsy or autopsy provided material for examination, approximately 25 per cent, were squamous, 20 per cent, glandular and 55 per cent, undifferentiated cancer. It is interesting to note that Gazyerli13 has described marked calcification as a common finding in lung tumours, a point which has possible bearing on the effect of radiation because of increased absorption. Photomicrographs of sections from our cases illustrate different .types. Fig. 15 B. Malignant Tumours of the Mediastinum. Under this heading are included lymphosarcoma (two cases), Hodgkin's lymphadenoma (six cases), malignant tumours of the thymus (two cases), teratoma, neurogenic tumours (one case), sarcoma (one case), secondary deposits, and the rare but possible carcinoma in a retrosternal thyroid.
It is not possible to give the number of cases which showed secondary deposits in the mediastinum, but this was a common finding. By far the most numerous of these tumours are the primary neoplasma of lymph nodes. I use this term to cover lymphosarcoma and Hodgkin's lymphadenoma, because it may be almost impossible to tell from clinical examination whether a gradually enlarging mass of glands is chronic inflammatory or lymphosarcoma of the slowly growing type composed of cells somewhat differentiated towards small It shows fibroblasts, a few giant cells and many eosinophile cells and almost complete absence of mitosis, and, in spite of the unusual clinical appearance and the invasion of muscle, is probably lymphadenoma.
There has been no case of the condition described as thymic carcinoma, said to originate in the glandular tissue represented in adult life by Hassall's corpuscles. It is now generally believed that cases so described are probably secondary to bronchial carcinoma, and the section (Fig. 6 ) suggests another possibility of error, the similarity of epithelial and reticulum-cell forms.
Teratoma of the mediastinum is essentially a dermoid type and malignant changes in such tumours have been recorded. True teratoma with elements derived from all three embryonic layers is rare, but does seem to occur. In this series, although some Cases have also been recorded where osteogenic sarcoma or fibrosarcoma of the spine or ribs has produced the syndrome, and I have seen it in cases of cancer of the breast with secondary involvement of supraclavicular lymph nodes and in a case of lymphosarcoma in this region.
C. Malignant Tumours of the Pleura.
These are comparatively rare, and in this series there is only one case which can reasonably be placed in the group and one diagnosed by histological examination of biopsy material from a secondary deposit in an inguinal lymph node as " probably pleural endothelioma." The other two pleural tumours are fibrosarcomas of rib.
The nature of primary pleural tumours has given rise to considerable controversy. Ewing elements are present they are still derived from the mesothelium.
The possibility, however, that tumours apparently primary in the pleura may be secondary to bronchial carcinoma is shown by our case, Figs, i, 2. Against this theory of origin from pleural endothelium is Willis,28 who quotes Robertson : " At least so far as the pleura is concerned, no diagnosis of primary carcinoma or mesothelioma or endothelioma can be justified on any logical ground," and adds, " with this conclusion, sweeping though it is, I completely concur." This view has had considerable support, and some observers have attempted to steer a middle course by diagnosing these doubtful tumours as angioblastoma or angiosarcoma. The cells lining the blood and lymph vessels and those lining the serous spaces are all derived from a common mesenchymal ancestor, so this gives another name to a tumour which does not rule out the old name, pleural endothelioma, and is less informative.
When the early cases of this series were being reviewed I was inclined to agree with Willis, but the structure of the tumour illustrated in Fig. 3 cannot, to my mind, be explained unless we accept the fact that a neoplasm of the cells lining the pleural serous cavity is an endothelioma. Histologically, it is a perivascular tumour growth with the characteristic cells already described. The biopsy was taken from an axillary lymph node which showed no connection with the primary growth lying deep to it within the thorax. Another less convincing example showed cells of the same type in a tumour in which the blood vessels were very prominent. The perivascular arrangement was not so marked, but this was a very malignant tumour. There is a possibility that it might be a primary fibrosarcoma of rib, but in our example of a true fibrosarcoma of rib there were multiple secondary deposits in the lung in contradistinction to the endotheliomas which both produced secondaries in lymph nodes.
II. Treatment.
Two methods of treatment, surgery and radon seed implantation through the bronchoscope, claim a few successes, but these are only applicable at a stage of tumour growth so early that the diagnosis of neoplasm is rarely made. As a rule, the only therapy which can be considered is external radiation with X-rays. I have already pointed out that the 104 ? possibility of obtaining a cure depends on the pathology of the ^sion. This has been discussed, and for the sake of clearness, I recapitulate. In the lung the tumours are primary bronchial carcinoma, or secondary metastatic deposits. Bronchial carcinoma varies in type and in degree of differentiation, and in a large proportion of cases produces early metastases.
Tumours of the mediastinum are primary tumours of lymph nodes or thymus, secondary deposits in lymph nodes, or unusual neoplasma. Primary tumours of the pleura are endotheliomas. Taking this rough classification, it will seem possible to determine methods of treatment. First, however, is advisable to make clear my conception of certain factors affecting the general principles of radiation therapy : (i) radiosensitivity ; (2) minimal lethal dose ; (3) time factor? particularly as they apply to the treatment of these tumours.
(1) Radiosensitivity.?This is a phenomenon for which many explanations are offered, but so long as the central problem of the biological effect of irradiating the cell remains unsolved, any classification of malignant tumours in relation to their radiosensitivity affords a rather uncertain basis for modifications of dosage. It is not clear whether the term ' radiosensitive " as generally used is intended to be synonymous with " radiocurability," or simply with the rapidity of disappearance of the obvious tumour. Cancer is a local disease in the first place, and any treatment so far devised is intended to cure the local manifestations. The term " radio- is also open to misconception, and for convenience we may take it to mean that the patient is alive and symptom-free five years after treatment.
It is probable that radiosensitivity can be related to the cytology and to the biochemical and biophysical processes in the cell, but the effects of radiation on the individual tumours described are linked with the other factors described below.
(2) Minimal Lethal Dose.?The minimal lethal dose must be measured by physical and assessed by biological methods. A statement of the dose in Roentgens measured with back-1 scatter is now accepted by most radiologists as a reasonably accurate measure of the energy absorbed by the tissues in the position defined, and I shall assume in this discussion that a 105 dose expressed in Roentgens (" r") will be regarded as a definite quantity of radiation without further description.
For success, the dose must be directly or indirectly lethal to all the cells of a tumour, and the question arises whether it is possible to ascertain the lethal dose for any type of tumour. This raises the further question?what are tumours of any one type ? Squamous cell cancer of the skin may probably be so regarded, and MacWhirter 29 and Ham 30 have suggested that it is possible to determine an approximate minimal lethal dose.
Most histologists now accept the view of Maximow 7 and Krompecher 31 that there are small stem or replacement cells for every tissue, the cells produced at the division of replacement cells differentiating or being determined in different directions according to the functions required. Where the function of an epithelial tissue is to protect, differentiation is as a rule to keratin formation ; in the specialised structure of the air passages, it is to the production of ciliated cells. When growth is malignant, differentiation is always incomplete, and ciliated cells are not produced ; the result of proliferation being either the metaplasia or anaplasia described in bronchial cancers. Anaplasia is rare in epitheliomas arising in the skin, but extremely anaplastic cancers may arise in the squamous epithelium of the mouth and throat, and anaplastic tumours are the commonest form of bronchial cancer. Anaplastic tumours are described by most observers as very radiosensitive, but it is much more difficult to determine whether they are radiocurable. Anaplasia is very rapid growth and absence of differentiation, and thus is associated with early metastases both by the lymph stream and the blood stream, and by the definition given, a cancer is no longer radiocurable if a distant metastasis is present. The whole question of sensitivity is complicated by metastasis. The thymic tumour shown in Figs. 5 and 6 was so sensitive that there was complete disappearance of the radiographic shadow, but the patient died of secondaries at an early date, and the absence of local recurrence cannot be accepted as proof of local cure. The same difficulty makes cytological grading of little value in estimating a lethal dose, although it helps to indicate whether tumour disappearance is likely to be obtained.
If we accept the position that there is a stem cell for all epithelial tissue, there is also a stem cell for all epithelial cancers, and our minimal lethal dose must be that dose which 106
Will destroy all the stem cells, the other cells being unimportant.
I do not suggest that there is a stem cell for all epithelial cancers m the sense that the properties and therefore the radiosensitivity ?f all stem cells are similar. In most tumours the stem cells are not pluripotential, but are already determined to the production of a particular type of cell. It is therefore permissible to suppose, although so far it is impossible to prove, that radiosensitivity varies with the function to which the cells are determined. According to this conception, the degree of differentiation may influence the rapidity with which a tumour disappears because very rapid growth and differentiation are incompatible, but it does not determine the dose necessary to destroy the stem cell. It has been frequently demonstrated that the sensitivity of a cell is at a maximum at some stage of mitotic division, and therefore a tissue in which large numbers of cells are in mitosis will be more easily damaged by radiation than a slowly growing tissue. Rapidity of growth depends on many factors?blood supply, blood plasma and tissue fluids as cultural media for cells, tissue spaces in which rapid proliferation is not mechanically restrained, functional activity of the tissue of origin, and probably other physical and chemical changes not yet sufficiently determined?but these factors are all independent of the stem cell. In the absence of proof to the contrary, I suggest that the minimal lethal dose is that dose which will lead to the destruction of all the stem cells of the tumour. The stem cells are all-important in this conception, and their determination to the production of cells of one type rather than another is then the morphological index for dosage, rather than the degree of differentiation. Such a conception, if valid, does seem to represent a simplification of procedure. The minimal lethal dose would then be determined on morphology and functional determination. An example has already been given by Paterson,32 who has suggested that there is a minimal lethal dose common to all squamous carcinomas. The probable figures are from 5500 " r " in five weeks to 7000 " r " in eight weeks, but it must be noted that doses of radiation can only be given if the number of days over which they are delivered is stated, because dosage is definitely related to time.
Before discussing the question of the relation of minimal lethal dose to the time factor, reference must be made to the tumours other than epithelioma which have been described. I
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Bronchial cancers include those derived from mucus-secreting glands, and the different function may mean that the characters of the cell are entirely different. It is often stated that the cancer of glandular tissues is more radioresistant than epidermoid cancer, but this position has not been proved. Some forms of mammary cancer, glandular cancer of the uterine cervix, and in particular undifferentiated cancer of the thyroid, are sensitive, but the glandular cancers of the alimentary tract appear to be very resistant. The position of the tumour within the body, and the nature of the surrounding tissues are such important factors that the practical difficulties of radiating many of them are very great, and it remains almost impossible to foretell the response to radiation of a glandular cancer.
On the other hand, it is probable that their sensitivity is not greater than that of the epidermoid cancers, so the minimal lethal dose aimed at in their treatment should not be less.
Leaving aside the rare possibilities, only mediastinal and pleural tumours observed in this series will be discussed. They present various problems in their reaction to radiation, because they vary from a highly differentiated chondrosarcoma to neurocytoma, and to reticulum-cell sarcoma of the most primitive type. It has been pointed out that in normal differentiated tissues growth is probably the result of mitotic division of special replacement cells, and that their part in neoplasia may explain certain degrees of sensitivity, but in lymph nodes all the cells except the lymphocytes are potential replacement cells, so that when lymphoid tissue becomes neoplastic, as it does in reticulum-cell sarcoma, the population is very homogeneous, and there may be less individual variation. It is therefore probable that the minimal lethal dose for the tumour is less than that for tumours of epithelial tissues.
That lymphosarcoma is more sensitive is generally accepted and the methods evolved for treating large areas by thorax or trunk " baths " are made possible by the fact that enormous tumours disappear with doses of 2000 " r " in four to five weeks, or even with smaller doses. The precursor of reticulum cell and lymphoblast is the primitive mesenchymal cell, and the stem cell of the tumour must be a derivative of this. It is possible that this mesenchymal cell is the most sensitive of the normal tissue cells, a point suggested by the effect of radiation on the number of lymphocytes in the circulating 108 -J blood, and the stem cell of lymphosarcoma is proportionately sensitive. I have accepted Hodgkin's lymphadenoma as another Primary neoplasm of lymph nodes, and in spite of the difficulties ?f diagnosis it should be regarded as a tumour entity. All the elements in the lymph node are derived from the primitive Mesenchyme, but the precursor cell of Hodgkin's lymphadenoma, although a stem cell, shows " determination " to the production of fibroblasts. The minimal lethal dose for lymphadenoma is the dose which destroys these stem cells, and their sensitivity appears to lie between that of the stem cells ?f lymphosarcoma and the stem cell of epithelial cancer. These points have real importance, because it has been argued that the highest dose compatible with safety is the optimum dose. In the treatment of epithelial cancers, it is Probably true, because the margin between the minimal lethal and the maximum safe dose is very narrow, but for lymphosarcoma and lymphadenoma the outlook is different. The volume of tissue to be irradiated may determine the maximum safe dose at a low figure, but if the tumour is localised, it may be wisest to preserve the patient's resistance as far as possible. The two cases of thymic tumour in this series are interesting examples. The tumour shown in Figs. 13 and 14 was a lymphosarcoma, and half-way through treatment, when 2000 " r " had been delivered to the tumour the radiograph showed practically complete disappearance, but the dose was carried to 5000 " r " in the attempt to obtain sterilisation. Within a few weeks there were large deposits in the liver, and further radiation was not so well tolerated, and the patient died three rnonths later. The fatal outcome was probably inevitable, but m such a case,' dealing with a tumour known to be sensitive, I doubt whether a useful purpose was served by continuing to treat after the mass of neoplasm had disappeared. The other tumour shown in Fig. 22 was probably lymphadenoma, and proved to be more resistant.
It was complicated by the appearance of axillary and inguinal node involvement and the progress of the disease was typical, with death six months later from cachexia. The one neurogenic tumour in the series was not irradiated, and the chondrosarcoma was unchanged after a tumour dose of 1500 The other case of malignant endothelioma was sensitive so far as the primary growth was concerned, but secondary involvement of lymph nodes caused death five months after the start of treatment.
(3) The Time Factor.?When a minimal lethal dose is stated, it is always necessary to specify the time in which it is given, because a dose which would be lethal if given in one treatment would not be lethal if spread over a week. The effect of time is now accepted as an integral part of radiation therapy, but the reason for the greater increase in the tolerance of normal tissue as compared with tumour tissue is not clearly understood. It is believed that normal tissues recover more quickly and more completely than do tumour tissues, so that it is possible to find a dose which, given at sufficiently frequent intervals over a fixed period, will prevent recovery of the injured tumour, but will avoid permanent damage to normal tissues. The question of time is thus related to the response of the normal tissues to the injury of radiation. The normal mechanism of response to injury, dilatation of vessels, increased blood supply to the part, and the appearance of macrophages, fibroblasts, and sprouting blood vessels will be the first step in repair. It is thought that when a tumour is rapidly absorbed, many of the cells are completely lysed, and are carried away by the circulating fluids. It is also possible that some cells are not completely destroyed, but are deprived of nourishment by fibroblasts, and engulfed by macrophages, although it is believed that only dead cells have been seen within macrophages. If this be the case, it is essential that the normal I reaction of the reticuloendothelial cells should not be prevented, and it is possible that the minimal lethal dose is not simply the destructive dose, but an optimum dose which, when spread over a suitable period of time, destroys a proportion of cells, and so damages the rest that they are removed and replaced by the normal process of tissue repair. Methods of irradiating the lung and results of treatment vary considerably, and so far the number of five-year survivals ls so small that statistical tables to show survival rates are not Worth while.
Holfelder33 records ten cases. Only four of these were section-proved, but all showed the typical radiographic picture ?f bronchial cancer. Two cases were alive after five years, and one after three and a half years, but all were without biopsy. One proved cancer lived four and one fifteen months symptom-free. The others all showed resolution of the primary growth but developed secondaries. Herrnheiser34 had five cases symptom-free for from three months to two and a half years, but only one had a biopsy and the diagnosis was angioendothelioma. No improvement was noted in four cases ?f squamous epithelioma, and it was observed that sepsis with abscess formation and even gangrene followed irradiation.
Chandler and his co-workers35 record fifty-six cases, fortyfour of which were treated with X-ray and twelve with radon, twenty-three of them with marked benefit. Five cases were alive thirty-five months after treatment, three died after thirty-six, seventeen and sixteen months. The others all died within the year in spite of the improvement. Leddy and Vinson 36 were able to treat forty-two out of seventy-one cases, and ten of the treated cases were alive and improved an average of fifteen months after treatment ; all were section-proved. Fulton37 out of thirty-six cases referred for treatment found five too advanced for any therapy and sixteen for whom only palliation was possible. In the remaining fifteen a full course was attempted, but only eight were able to complete it. Of these, four were alive and symptom-free from seven to twelve months after, and four died from metastases with an average survival of eleven months.
The number of cases treated in Edinburgh is very small. Five cases of bronchial cancer lived for from twelve to eighteen months after treatment, and one case is alive and symptom-free a year after treatment.
All these therapists agree on the necessity of attempting to obtain a lethal dose.
Herrnheiser had no success with a " total dose to skin " of less than 9000 " r." Finzi advises 250 to 300 per cent, of S.E.D. to tumour, and Fulton gives Fortunately, although the prognosis in all the tumours discussed is bad, the decision as to treatment is not difficult because, if the general condition is not already so poor that the patient is unable to support any active therapy, the palliative effects of radiation are nearly always considerable. In bronchial cancers the reduction in the size of the tumour may allow the lung to re-expand, dyspnoea is relieved, and often the cough and sputum are diminished. As was already pointed out by Paterson,4J squamous-cell cancer presents a special problem because of the tendency to break down already described, but it does not produce such early metastases, so that there is always the possibility that it is still localised. If diagnosis has been uncertain, the response to radiation may be so good as to suggest that the tumour is a lymphoblastoma. Again the right method has been used because palliation has been obtained with just that chance, pointed out by Levitt,42 that this is the primary manifestation of the tumour of lymph nodes, and that having received a lethal dose at an early stage 112 -Tumours of the Lun?\ Mediastinum and Pleura !t will not produce secondaries. Even if the diagnosis is not in doubt and the enlarged mediastinal nodes are only ?ne part of an extensive neoplastic process, the pressure symptoms are so distressing that treatment is nearly always called for.
Although it may be easy to decide to treat, the question ?f the dose to be administered is not so simple. I have said that in my opinion a minimal lethal dose for bronchial cancer ls approximately 6000 " r " in six weeks, but I believe that this dose can only be delivered if it is possible to cover the entire tumour with small fields. If a high volume of tissue must be raised to the high dosage, there will be marked radiation effects ?n the lung, together with changes in the blood, which may endanger life before the full dose has been delivered. The ideal case for curative treatment is the small well-defined mass over the hilum, because the lymph nodes at the hilum are involved in such a high proportion of cases that the hilar area must be included.
In case of doubt, treatment can be started with large fields. If the response is good, the fields can be changed, when 2500 to 3000 " r " has been given. If the response is not good, palliation only is attempted, and treatment is stopped at about 3000 " r." The higher dose may prolong life without real palliation ; one case, for instance, lived for eighteen months, but with a lung abscess and gradually increasing fibrosis causing most distressing dyspnoea. Out of thirty-five cases treated at another hospital (Manchester) for palliation only, genuine improvement was obtained in nineteen cases.
Out of three cases given full doses, only one had life prolonged for over a year, and the relief of symptoms was less than with palliative dosage. Occasionally the problem of irradiating secondary deposits in the lung or mediastinum arises, and the advisability of attempting treatment depends on the probable sensitivity of the primary growth. Cases have been recorded of very sensitive embryonal tumours such as seminoma which have remained well for years after irradiation of lung metastases, and even if this happy result is rare there is again the possibility of relieving suffering. Three cases of seminoma of the testis secondary in the lung were treated in our series, and two were very much relieved until liver involvement became obvious. A case of secondary deposits following osteogenic sarcoma was admitted with extreme dyspnoea, and was so N.S. IV.. XLVT. NO. II.
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H 2 much improved, in spite of the fact that the masses showed little diminution, that she lived a normal life for six months, then died after ten days with symptoms simulating pneumonia.
Conclusions.
I have tried to analyse the cases in the literature, and to record my own observations, keeping in mind the lay point of view which is not concerned with post-mortem details, but wishes to know the prospect of cure or palliation in this form of cancer, of which much is now heard. Definite conclusions are difficult to draw, but I believe these suggestions may be accepted 1. The important malignant neoplasms within the thorax are bronchial carcinoma, primary neoplasms of lymph nodes and metastatic tumours. Other tumours such as neurocytoma, teratoma, osteogenic sarcoma and endothelioma are so rare as to be less important from the point of view of treatment.
2. The origin and method of growth is important in relation to the response of the tumour to radiation.
3. As soon as the diagnosis of intrathoracic neoplasm has been made, X-ray therapy should be started.
4. If it is at all possible, a lethal dose should be delivered to the tumour, but before this is attempted obvious metastases should be excluded by careful clinical and radiological examination.
5. For bronchial cancer the tumour dose should not be less than 6000 " r " in six weeks ; for primary neoplasms of lymph nodes it should be from 2500 to 4000 " r " in five to six weeks, according to the size of field which has to be used ; for the rare tumours it is probably wise to aim at delivering 6000 " r " in six weeks, if radiation is undertaken at all. 6. Cure is only possible in very favourable cases ; if the tumour is too large to be treated with small fields and remains so after 2500 " r " has been delivered, only palliation is possible. 7. Even if metastases are known to be present in bronchial J cancer or multiple involvement in primary neoplasm of lymph nodes, when the growth is secondary to a neoplasm elsewhere, palliation should be attempted. 8 . If treatment is palliative, it is essential to avoid reactions which will increase the patient's discomfort.
